Loading...
•
Jun 30, 2021
TransMedics Q2 2021 Earnings Report
TransMedics' financial performance increased significantly in Q2 2021, driven by strong OCS Lung and Heart sales and FDA milestones.
Key Takeaways
TransMedics reported a strong second quarter with a 141% increase in net revenue compared to the previous year. The company achieved key milestones, including positive FDA advisory committee votes for the OCS Liver System and 510(k) clearance of the OCS Lung Solution. Increased operating expenses led to a net loss of $10.7 million.
Net revenue reached $8.2 million, a 141% increase year-over-year.
Gross margin improved to 68% compared to 56% in the second quarter of 2020.
Operating expenses increased to $15.5 million due to investments in the National OCS Program and FDA advisory committee preparations.
Net loss was $10.7 million, compared to $8.5 million in the second quarter of 2020.
Forward Guidance
The company remains confident in its long-term outlook and its unique ability to transform organ transplantation globally.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...